Cutaneous neurofibromas (cNF) are an urgent unmet need for people living with the complex syndrome of NF1. Patients with NF1 often identify cNF as their greatest burden related to the condition. The Neurofibromatosis Therapeutic Acceleration Program (NTAP) is launching a new initiative to advancing meaningful therapeutic discovery for NF1 associated cNF: the Biology and Therapeutic Development for Cutaneous Neurofibromas Initiative.
A core element of this new cNF initiative is the Request of Applications for research projects focused on cNF. The letters of intent for this opportunity are due August 5, 2022. Please review the full RFA for the 2022 Biology and Therapeutic Development for Cutaneous Neurofibroma announcement for details about the application and funding.
